Skip to main content

NeuroSense Therapeutics Ltd.

NRSNW
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001875091

No open-market purchases or sales by NeuroSense Therapeutics Ltd. insiders were filed in the last 90 days; 3 institutions reported holding it in 13F filings for Q2 2026, worth $10.4K in total; no superinvestor holds it.

Other share classesNRSN

Key figures

Insider buysOpen market, last 90 days
0
Insider sellsOpen market, last 90 days
0
13F holdersQ2 2026, 0 vs. previous quarter
3
13F valueReported value at the end of Q2 2026
$10.4K
Superinvestors holdingAt the end of Q2 2026
0

Price chart

Superinvestors holding NRSNW, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding NRSNW at the end of Q2 2026.

Latest insider trades

Open-market purchases and sales by NeuroSense Therapeutics Ltd. insiders from Form 4, newest first.

See all insider trades
Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jun 17, 2026 (view filing)Jun 161 dayBen-Noon AlonChief Executive OfficerPPurchase+250.0K$0.80+$200.0K+5.8%4.53M after
Jun 17, 2026 (view filing)Jun 161 dayEisenberg OrChief Financial OfficerPPurchase+250.0K$0.80+$200.0K+19.9%1.50M after

Top 10 13F holders, Q2 2026

The largest institutional positions in NeuroSense Therapeutics Ltd. at the end of Q2 2026; share changes are against Q1 2026.

See all 3 holders
Institutions holding NRSNW in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Empery Asset Management, LP100,402$6.33K0.01%00.0%Unchanged
Clear Street Group Inc.63,085$3.97K0.00%−300−0.5%Reduced
UBS Group AG1,163$730.00%00.0%Unchanged